한빛사논문
Hyo In Kim a,1, Yohan Han b,1, Mi-Hye Kim c,1, Mina Boo d, Kwang-Jin Cho d, Hye-Lin Kim e, In-Seon Lee d,e, Ji Hoon Jung d,e, Woojin Kim d,e,f, Jae-Young Um d,e, Jinbong Park d,e,f, Seong-Gyu Ko d,e,f
aBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
bDepartment of Microbiology and Sarcopenia Total Solution Center, Wonkwang University School of Medicine, Iksan, Republic of Korea
cCollege of Korean Medicine, Woosuk University, Jeonju, Republic of Korea
dDepartment of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea
eCollege of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
fKorean Medicine-Based Drug Repositioning Cancer Research Center, Kyung Hee University, Seoul, Republic of Korea
1These authors contributed equally to this study and share first authorship.
Corresponding authors : Jinbong Park, Jinbong Park
Abstract
Background
Acute lung injury (ALI) is a devastating condition caused by sepsis, pneumonia, trauma, and more recently, COVID-19. SH003, an herbal formula consisted of Astragalus membranaceus, Angelica gigas and Trichosanthes kirilowii, is known for its effects on cancer and immunoregulation.
Hypothesis/Purpose
Previous studies show SH003 exerts a promising anti-inflammatory effect. This study investigates the effect of modified SH003 on ALI using in silico, in vivo, and in vitro models.
Study Design and Methods
We performed in silico-based analysis of SH003 on ALI-related pathways. C57BL/6 mice were intraperitoneally subjected to lipopolysaccharide (LPS) to induce septic ALI, followed by oral administration of SH003 for 2 weeks. Dexamethasone was used as the positive control. Human peripheral blood-derived polymorphonuclear neutrophils (PMN) were used to investigate the effect and mechanisms of SH003 on neutrophil extracellular trap (NET) formation.
Results
Network pharmacology analysis suggested SH003 regulates lung inflammation by modulating NET formation. SH003 significantly reduced mortality in sepsis in vivo by inhibiting local and systemic inflammation, likely via nuclear factor kappa B and mitogen-activated protein kinase pathways-mediated inflammasome suppression. SH003 also decreased NET-related markers in lung tissues and inhibited LPS- and phorbol myristate acetate-induced NET formation in PMN. Cytometry time-of-flight analysis confirmed regulation of NETosis-related pathways by SH003.
Conclusion
SH003 effectively inhibits excessive immune responses in the lung by suppressing inflammasome activation and NET formation. These findings suggest SH003 as a potential therapeutic agent for septic ALI.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기